Brain Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older.
• People with a general health status rated as fully active or able to carry out light work (WHO performance status 0 or 1).
• People who have been recommended for a type of targeted brain radiation treatment called stereotactic radiotherapy (SRT), following a decision by a specialist medical team.
• People whose brain metastases (cancer that has spread to the brain) come from a solid tumour with a confirmed tissue diagnosis — including cancers that are known to be harder to treat with radiation, such as kidney cancer, sarcoma, or melanoma.
• People with up to 5 brain metastases in total; people who have had surgery to remove a brain metastasis and have 1 to 4 remaining lesions may also be eligible.
• People with at least one and no more than 5 target brain lesions measuring between 10mm and 25mm in size.
• People whose total combined tumour volume in the brain does not exceed 30 cubic centimetres.
• People with normal blood test results (full blood count).
• People whose brain metastases are not actively bleeding and who do not have cancer spread to the membranes surrounding the brain.
• People with brain metastases causing symptoms are still eligible.
• People who meet a minimum score on the DS-GPA scale (a medical scoring system used to assess outlook for people with brain metastases), with the required score varying depending on cancer type — the trial site can confirm the relevant threshold for each cancer type.
• People who are not currently receiving systemic (whole-body) cancer treatment, or who are able to pause such treatment for 3–7 days before and after radiation, depending on the medication and the treating doctor's judgement.
• People who are able to remain still enough during treatment to wear a fitted mask used to keep the head in place.
• People whose mental and cognitive abilities allow them to follow the study requirements.
• Women who could become pregnant must be using adequate contraception.
• People who have signed the informed consent form agreeing to take part.
• People who are enrolled in the French social security system.

Who may not be able to join:

• People with a current diagnosis or history (within the last 5 years) of small cell lung cancer, germ-cell tumours, lymphoma, leukaemia, or multiple myeloma.
• People whose brain metastases are located in the brain stem or within 1 centimetre of the optic nerves or related structures involved in vision.
• People who have a neurodegenerative disease (such as a condition that causes progressive loss of nerve function).
• People who require long-term corticosteroid (steroid) use for reasons unrelated to their brain metastases or cancer.
• People who cannot have a brain MRI scan, or who cannot receive the contrast dyes used during MRI or CT imaging.
• People with a known allergy to contrast imaging agents or their ingredients.
• People who have previously received stereotactic radiation treatment to the brain.
• People who have previously had whole-brain radiation treatment.
• People whose brain metastases are actively bleeding.
• People currently receiving anti-angiogenic treatments (medications that reduce blood vessel growth), unless that treatment can be paused 3–7 days before and after radiation.
• People whose brain lesions are so close together that treating one would deliver a high radiation dose (above 5 Gy) to another lesion at the same time.
• People who are under legal guardianship or have had their freedom restricted.
• People who are pregnant or breastfeeding.
• People whose geographical location, social circumstances, or psychological condition may make it difficult to participate fully in the study.
• People who have participated in another therapeutic clinical trial within the last 30 days.

Important: Always verify eligibility with the trial site directly before applying.